QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

This is a single-arm, single-center, interventional, dose-escalation clinical study designed to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Trial Details

NCT ID
NCT06056752
Phase
PHASE1
Sponsor
Anhui Provincial Hospital
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • QH103 Cell Injection
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • Age ≥14 years, gender is not limited;
  • Patients with clinically diagnosed relapsed/refractory B-ALL (except those presenting with extramedullary disease only), including any of the follo…
  • Failure to obtain CR after 2 cycles of standard chemotherapy;
  • First induction of CR, but duration of CR is ≤12 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →